Is endothelial nitric oxide synthase a moonlighting protein whose day job is cholesterol sulfate synthesis? Implications for cholesterol transport, diabetes and cardiovascular disease

Entropy

Volumn 14, Issue 12, 2012, Pages 2492-2530

  Seneff, Stephanie ^a   Lauritzen, Ann ^b   Davidson, Robert ^c   Lentz Marino, Laurie ^d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Independent Researcher   (United States)

^c PhyNet Inc   (United States)

^d MOUNT HOLYOKE COLLEGE   (United States)

Author keywords

Autophagy; Cardiovascular disease; Cholesterol sulfate; Diabetes; endothelial nitric oxide synthase; Glycosaminoglycans; Heparan sulfate; Hydrogen sulfide; Lysosomes; Nitric oxide

Indexed keywords

EID: 84871586028     PISSN: None     EISSN: 10994300     Source Type: Journal    
DOI: 10.3390/e14122492     Document Type: Review

References (215)

1. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: Structure, function and inhibition. Biochem. J. 2001, 357, 593-615.
2. Nathan, C.; Xie, Q. Nitric oxide synthases: Roles, tolls and controls. Cell 1994, 78, 915-918.
3. Florio, T.; Arena, S.; Pattarozzi, A.; Thellung, S.; Corsaro, A.; Villa, V.; Massa, A.; Diana, F.; Spoto, G.; Forcella, S.; et al. Basic fibroblast growth factor activates endothelial nitric-oxide synthase in CHO-K1 cells via the activation of ceramide synthesis. Mol. Pharmacol. 2003, 63, 297-310.
4. Feron, O.; Saldana, F.; Michel, J.B.; Michel, T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J. Biol. Chem. 1998, 273, 3125-3128.
5. Randriamboavonjy, V.; Fleming, I. Endothelial nitric oxide synthase (eNOS) in platelets: How is it regulated and what is it doing there? Pharmacol. Rep. 2005, 57, 59-65.
6. Kleinbongard, P.; Schulz, R.; Rassaf, T.; Lauer, T.; Dejam, A.; Jax, T.; Kumara, I.; Gharini, P.; Kabanova, S.; Özüyaman, B.; et al. Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006, 107, 2943-2951.
7. Ju, H.; Zou, R.; Venema, V.J.; Venema, R.C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem. 1997, 272, 18522-18525.
8. Simons, K.; Sampaio, J.L. Membrane Organization and Lipid Rafts. Cold Spring Harb. Perspect. Biol. 2011, 3, a004697.
9. Pike, L.J. Lipid rafts: Bringing order to chaos. J. Lipid Res. 2003, 44, 655-667.
10. Gross, S.; Jones, C.; Hattori, Y.; Raman, C. Tetrahydrobiopterin: An essential co-factor of nitric oxide synthase with an elusive role. In Nitric Oxide Biology and Pathobiology; Jignarro, L., Ed.; Academic Press: San Diego, CA, USA, 2000.
11. Rafikov, R.; Fonseca, F.V.; Kumar, S.; Pardo, D.; Darragh, C.; Elms, S.; Fulton, D.; Black, S.M. eNOS activation and NO function: Structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J. Endocrinol. 2011, 210, 271-284.
12. Kawasaki, K.; Smith, R.S., Jr.; Hsieh, C.-M.; Sun, J.; Chao, J.; Liao, J.K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell. Biol. 2003, 23, 5726-5737.
13. Zou, M.-H.; Shi, C.; Cohen, R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest. 2002, 109, 817-826.
14. Dimmeler, S.; Lottspeich, F.; Brüne, B. Nitric oxide causes ADP-ribosylationand inhibition of glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 1992, 267, 16771-16774.
15. OBrien, M.L.; Tew, K.D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer 1996, 32A, 967-978.
16. Mayer, B.; Pfeiffer, S.; Schrammel , A.; Koesling, D.; Schmidt, K.; Brunner, F. A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione. J. Biol. Chem. 1998, 273, 3264-3270.
17. Guix, F.X.; Uribesalgo, I.; Coma, M.; Muñoz, F.J. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 2005, 76, 126-152.
18. Sarkar, S.; Korolchuk, V.I.; Renna, M.; Imarisio, S.; Fleming, A.; Williams, A.; Garcia-Arencibia, M.; Rose, C.; Luo, S.; Underwood, B.R.; et al. Complex Inhibitory Effects of Nitric Oxide on Autophagy. Mol. Cell 2011, 43, 19-32.
19. Takemura, G.; Miyata, S.; Kawase, Y.; Okada, H.; Maruyama, R.; Fujiwara, H. Autophagic Degeneration and Death of Cardiomyocytes in Heart Failure. Autophagy 2006, 2, 212-214.
20. Jeffery, C.J. Moonlighting proteins: Old proteins learning new tricks. Trends Genet. 2003, 19, 415-417.
21. Bishop, J.R.; Schuksz, M.; Esko, J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446, 1030-1037.
22. Teien, A.N.; Abildgaard, U.; HÖÖk, M. The anticoagulant effect of heparansulfate and dermatan sulfate. Thromb. Res. 1976, 8, 859-867.
23. Shriver, Z.; Liu, D.; Sasisekharan, R. Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovas. Med. 2002, 12, 71-77.
24. Deng, D.; Jiang, N.; Hao, S.J.; Sun, H.; Zhang, G.J. Loss of membrane cholesterol influences lysosomal permeability to potassium ions and protons. Biochim. Biophys. Acta 2009, 1788, 470-476.
25. Jadot, M.; Andrianaivo, F.; Dubois, F.; Wattiaux, R. Effects of methylcyclodextrin on lysosomes. Eur. J. Biochem. 2001, 268, 1392-1399.
26. Egeberg, M.; Kjeken, R.; Kolset, S.O.; Berg, T.; Prydz, K. Internalization and stepwise degradation of heparan sulfate proteoglycans in rat hepatocytes. Biochim. Biophys. Acta 2001, 1541, 135-149.
27. Harper, G.S.; Rozaklis, T.; Bielicki, J.; Hopwood, J. Lysosomal sulfate efflux following glycosaminoglycan degradation: Measurements in enzyme-supplemented Maroteaux-Lamy syndrome fibroblasts and isolated lysosomes. Glycoconjugate J. 1993, 10, 407-415.
28. Jeyakumar, M.; Dwek, R.A.; Butters, T.D.; Platt, F.M. Storage solutions: Treating lysosomal disorders of the brain. Nature Rev. Neurosci. 2005, 6, 1-12.
29. Hopwood, J.J.; Ballabio, A. Multiple sulfatase deficiency and the nature of the sulfatase family. In The Metabolic and Molecular Basis of Inherited Disease. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.; McGraw-Hill: Columbus, OH, USA, 2001; pp. 3725-3732.
30. Strott, C.A. Cholesterol sulfate in human physiology: What's it all about? J. Lipid Res. 2003, 44, 1268-1278.
31. Rodriguez, W.V.; Wheeler, J.J.; Klimuk, S.K.; Kitson, C.N.; Hope, M.J. Transbi-layer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes. Biochemistry 1995, 34, 6208-6217.
32. Haines, T.H. Do sterols reduce proton and sodium leaks through lipid bilayers? Prog. Lipid Res. 2001, 40, 299-324.
33. Astrup, J.; Sørensen, P.M.; Sørensen, H.R. Oxygen and glucose consumption related to Na+-K+ transport in canine brain. Stroke 1981, 12, 726-730.
34. Chen, Y.; Li, X.; Ye, Q.; Tian, J.; Jing, R.; Xie, Z. Regulation of α1 Na/K-ATPase expression by cholesterol. J. Biol. Chem. 2011, 286, 15517-15524.
35. Benarroch, E.E. Na+, K+ ATPase: Functions in the nervous system and involvement in neurologic disease. Neurology 2011, 76, 287-293.
36. Hao, S.J.; Hou, J.F.; Jiang, N.; Zhang, G.J. Loss of membrane cholesterol affects lysosomal osmotic stability. Gen. Physiol. Biophys. 2008, 27, 278-283.
37. Yang, A.J.; Chandswangbhuvana, D.; Margol, L.; Glabe, C.G. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1-42 pathogenesis. J. Neurosci. Res. 1998, 52, 691-698.
38. Simonaro, C.M.; Haskins, M.E.; Schuchman, E.H. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: A possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab. Invest. 2001, 81, 1319-1328.
39. Przybylska, M.; Faber, M.; Zaborowski, A.; Tosawski, J.; Bryszewska, M. Morphological changes of human erythrocytes induced by cholesterol sulphate. Clin. Biochem. 1998, 31, 73-79.
40. Cignarelli, M.; Damato, A.; Cospite, M.R.; Guastamacchia, E.; Nardelli, G.M.; Giorgino, R. Erythrocyte cholesterol and red blood cells: Deformability in diabetes mellitus. Boll. Soc. Ital. Biol. Sper. 1982, 58, 1115-1118.
41. Nakae, H.; Hanyu, O.; Fuda, H.; Strott, C.A. Novel role of cholesterol sulfate in gene regulation during skin development. FASEB J. 2008, 22, 782.
42. McGrath, J.A.; Uitto, J. The filaggrin story: Novel insights into skin-barrier function and disease. Trends Molec. Med. 2007, 14, 20-26.
43. Aleksandrov, D.A.; Sud'ina, G.F. Suppression of 5-Lipoxygenase Activity by Anionic Cholesterol Derivatives. (in Russian) Biochemistry (Mosc.) Supplement Series B: Biomed. Khim. 2007, 1, 168-171.
44. Langlais, J.; Zollinger, M.; Plante, L.; Chapdelaine, A.; Bleau, G.; Roberts, K.D. Localization of cholesteryl sulfate in human spermatozoa in support of a hypothesis for the mechanism of capacitation. Proc. Natl. Acad. Sci. USA 1981, 78, 7266-7270.
45. Lin, B.; Kubushiro, K.; Akiba, Y.; Cui, Y.; Tsukazaki, K.; Nozawa, S.; Iwamori, M. Alteration of acidic lipids in human sera during the course of pregnancy: Characteristic increase in the concentration of cholesterol sulfate. J. Chromatog. B 1997, 704, 99-104.
46. Seneff, S.; Davidson, R.; Mascitelli, L. Might cholesterol sulfate deficiency contribute to the development of autistic spectrum disorder? Med. Hypotheses 2012, 78, 213-217.
47. Tierney, E.; Bukelis, I.; Thompson, R.; Ahmed, K.; Aneja, A.; Kratz, L.; Kelley, R. Abnormalities of cholesterol metabolism in autism spectrum disorders. Amer. J. Med. Genet. B 2006, 141B, 666-668.
48. Waring, R.H.; Klovrza, L.V. Sulphur metabolism in autism. J. Nutr. Environ. Med. 2000, 10, 25-32.
49. Tai, S.C.; Robb, G.B.; Marsden, P.A. Endothelial Nitric oxide Synthase: A new paradigm for gene regulation in the injured blood vessel. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 405-412.
50. Marletta, M.A. Another activation switch for endothelial nitric oxide synthase: why does it have to be so complicated? Trends Biochem. Sci. 2001, 26, 519-521.
51. Marzinzig, M.; Nussler, A.K.; Stadler, J.; Marzinzig, E.; Barthlen, W.; Nussler, N.C.; Beger, H.G.; Morris, S.M., Jr.; Brückner, U.B. Improved methods to measure end products of nitric oxide in biological fluids: nitrite, nitrate, and S-nitrosothiols. Nitric Oxide 1997, 1, 177-189.
52. Pfennig, N.; Biebel, H. The dissimilatory sulfate-reducing bacteria. In The prokaryotes: A Handbook on Habitats, Isolation and Identification of Bacteria; Springer-Verlag: New York, NY, USA, 1986.
53. Hockin, S.L.; Gadd, G.M. Linked redox precipitation of sulfur and selenium under anaerobic conditions by sulfate-reducing bacterial biofilms. Appl. Environ. Microbiol. 2003, 69, 7063-7072.
54. Teske, A.; Ramsing, N.B.; Habicht, K.; Fukui, M.; Kver, J.; Jrgensen, B.B.; Cohen, Y. Sulfatereducing bacteria and their activities in cyanobacterial mats of Solar Lake (Sinai, Egypt). Appl. Environ. Microbiol. 1998, 64, 2943-2951.
55. Wahlund, T.M.; Woese, C.R.; Castenholz, R.W.; Madigan, M.T. A thermophilic green sulfur bacterium from New Zealand Hot Springs, Chlorobium tepidum sp. Arch. Microbiol. 1991, 159, 81-90.
56. Olson, J.M.; Blankenship, R.E. Thinking about the evolution of photosynthesis. Photosynth. Res. 2004, 80, 373-386.
57. Brune, D. Sulfur compounds as photosynthetic electron donors. Photosynth. Res. 2004, 2, 847-870.
58. Moss, M.; Waring, R.H. The plasma cysteine/sulphate ratio: A possible clinical biomarker. J. Nutr. Environ. Med. 2003, 13, 215-229.
59. Hildebrandt, T.M.; Grieshaber, M.K. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J. 2008, 275, 3352-3361.
60. Sorbo, B. Mechanism of oxidation of inorganic thiosulfate and thiosulfate esters in mammals. Acta Chem. Scand. 1964 18, 821-823.
61. Friedrich, C.G.; Rother, D.; Bardischewsky, F.; Quentmeier, A.; Fischer, J. Oxidation of reduced inorganic sulfur compounds by bacteria: Emergence of a common mechanism? Appl. Environ. Microbiol. 2001, 67, 2873-2882.
62. Bamford, V.A.; Bruno, S.; Rasmussen, T.; Appia-Ayme, C.; Cheesman, M.R.; Berks, B.C.; Hemmings, A.M. Structural basis for the oxidation of thiosulfate by a sulfur cycle enzyme. EMBO J. 2002, 21, 5599-5610.
63. Tapley, D.W.; Buettner, G.R.; Shick, J.M. Free radicals and chemiluminescence as products of the spontaneous oxidation of sulfide in seawater, and their biological implications. Biol. Bull. 1999, 196, 52-56.
64. Toohey, J.I. Derivative of cobalamin containing persulfide sulfur and glutathione. U.S. Patent 4,751,285, 1988.
65. Weinberg, J.B.; Chen, Y.; Jiang, N.; Beasley, B.E.; Salerno, J.C.; Ghosh, D.K. Inhibition of nitric oxide synthase by cobalamins and cobinamides. Free Radic. Biol. Med. 2009, 46, 1626-1632.
66. Hong, A.P.; Bahnemann, D.W.; Hoffman, M.R. Cobalt(II) tetrasulfophthalocyanine on titanium dioxide. 2. Kinetics and mechanisms of the photocatalytic oxidation of aqueous sulfur dioxide. J. Phys. Chem. 1987, 91, 6245-6251.
67. Chen, C.-A.; Wang, T.-Y.; Varadharaj, S.; Reyes, L.A.; Hermann, C.; Hassan Talukder, M.A.; Chen, Y.-R.; Druhan, L.J.; Zweier, J.L. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468, 1115-1120.
68. Zweier, J.L.; Chen, C.-A.; Druhan, L.J. S-glutathionylation reshapes our understanding of endothelial nitric oxide synthase uncoupling and nitric oxide/reactive oxygen species-mediated signaling. Antioxid. Redox Sign. 2011, 14, 1769-1775.
69. Jung, Y.; Marcus, R.A. On the Theory of Organic Catalysis "on Water". J. Am. Chem. Soc. 2007, 129, 5492-5502.
70. Markovitch, O.; Chen, H.; Izvekov, S.; Paesani, F.; Voth, G.A.; Agmon, N. Special Pair Dance and Partner Selection: Elementary Steps in Proton Transport in Liquid Water. J. Phys. Chem. B 2008, 112, 9456-9466.
71. Grossman, M.; Born, B.; Heyden, M.; Tworowski, D.; Fields, G.B.; Sagi, I.; Havenith, M. Correlated structural kinetics and retarded solvent dynamics at the metalloprotease active site. Nat. Struct. Mol. Biol. 2011, 18, 1102-1108.
72. Born, B.; Sagi, I.; Havenith, M. Water's contribution and enzyme's work: a KITA study. In Proceeding of Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues X, San Francisco, CA, USA, 21 January 2012.
73. O'Brien, J.T.; Prell, J.S.; Bush, M.F.; Williams, E.R. Sulfate Ion Patterns Water at Long Distance. J. Am .Chem. Soc. 2010, 132, 8248-8249.
74. Uittenbogaard, A.; Everson, W.V.; Matveev, S.V.; Smart, E.J. Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid- protein complex. J. Biol. Chem. 2002, 277, 4925-4931.
75. Fuda, H.; Javitt, N.B.; Mitamura, K.; Ikegawa, S.; Strott, C.A. Oxysterols are substrates for cholesterol sulfotransferase J. Lipid Res. 2007, 48, 1343-1352.
76. Gordon, T.; Castelli, W.P.; Hjortland, M.C.; Kannel, W.B.; Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 1977, 62, 707-714.
77. Castelli, W.P.; Garrison, R.J.; Wilson, P.W.; Abbott, R.D.; Kalousdian, S.; Kannel, W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J. Am. Med. Assoc. 1986, 256, 2835-2838.
78. Foster, M.; Samman, S. Zinc and redox signaling: Perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid. Redox Sign. 2010, 13, 1549-1573.
79. Stehouwer, C.D.A.; Weijenberg, M.P.; van den Berg, M.; Jakobs, C.; Feskens, E.J.M.; Kromhout, D. Serum Homocysteine and Risk of Coronary Heart Disease and Cerebrovascular Disease in Elderly Men. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1895-1901.
80. Krieger, M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J. Clin. Invest. 2001, 108, 793-797.
81. DeVries-Seimon, T.; Li, Y.; Yao, P.M.; Stone, E.; Wang, Y.; Davis, R.J.; Flavell, R.; Tabas, I. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. JCB 2005, 171, 61-73.
82. Tabas, I. Consequences of cellular cholesterol accumulation: Basic concepts and physiological implications. J. Clin. Invest. 2002, 110, 905-911.
83. Davidson, R.M.; Seneff, S. The initial common pathway of inflammation, disease, and death. Entropy 2012, 14, 1399-1442.
84. Kleinbongard, P.; Keymel, S.; Kelm, M. New functional aspects of the L-arginine-nitric oxide metabolism within the circulating blood. Thromb. Haemost. 2007, 98, 970-974.
85. Kang, E.S.; Ford, K.; Grokulsky, G.; Wang, Y.B.; Chiang, T.M.; Acchiardo, S.R. Normal circulating adult human red blood cells contain inactive NOS proteins. J. Lab. Clin. Med. 2000, 135, 444-451.
86. Campanella, M.E.; Chu, H.; Low, P.S. Assembly and regulation of a glycolytic enzyme complex on the human erythrocyte membrane. Proc. Natl. Acad. Sci. USA 2005, 102, 2402-2407.
87. Tsai, I.H.; Murthy, S.N.; Steck, T.L. Effect of red cell membrane binding on the catalytic activity of glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 1982, 257, 1438-1442.
88. Messana, I.; Orlando, M.; Cassiano, L.; Pennacchietti, L.; Zuppi, C.; Castagnola, M.; Giardina, B. Human erythrocyte metabolism is modulated by the O2-linked transition of hemoglobin. FEBS Lett. 1996, 390, 25-28.
89. Bleau, G.; Bodley, F.H.; Longpré, J.; Chapdelaine, A.; Roberts, K.D. Cholesterol sulfate. I. Occurrence and possible biological functions as an amphipathic lipid in the membrane of the human erythrocyte. Biochim. Biophys. Acta 1974, 352, 1-9.
90. Jennings, M.L. Rapid electrogenic sulfate-chloride exchange mediated by chemically modified band 3 in human erythrocytes. J. Gen. Physiol.1995, 105, 21-47.
91. Jagger, J.E.; Bateman, R.M.; Ellsworth, M.L.; Ellis, C.G. Role of erythrocyte in regulating local O2 delivery mediated by hemoglobin oxygenation. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H2833-H2839.
92. Gladwin, M.T.; Grubina, R.; Doyle, M.P. The new chemical biology of nitrite reactions with hemoglobin: R-state catalysis, oxidative denitrosylation, and nitrite reductase/anhydrase. Acc. Chem. Res. 2009, 42, 157-167.
93. Allen, B.W.; Piantadosi, C.A. How do red blood cells cause hypoxic vasodilation? The SNOhemoglobin paradigm. Am. Physiological Soc. 2006, 291, H1507-H1512.
94. Crawford, J.H.; Isbell, T.S.; Huang, Z.; Shiva, S.; Chacko, B.K.; Schechter, A.N.; Darley-Usmar, V.M.; Kerby, J.D.; Lang, J.D., Jr.; Kraus, D.; et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006 107, 566-574.
95. Jia, L.; Bonaventura, C.; Bonaventura, J.; Stamler, J.S. S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996, 380, 221-226.
96. Nagababu, E.; Ramasamy, S.; Rifkind, J.M. S-nitrosohemoglobin: A mechanism for its formation in conjunction with nitrite reduction by deoxyhemoglobin. Nitric Oxide 2006, 15, 20-29.
97. Nagababu, E.; Ramasamy, S.; Rifkind, J.M. Intermediates detected by visible spectroscopy during the reaction of nitrite with deoxyhemoglobin: The effect of nitrite concentration and diphosphoglycerate. Biochemistry 2007, 46, 11650-11659.
98. Cao, Z.; Bell, J.B.; Mohanty, J.G.; Nagababu, E.; Rifkind, J.M. Nitrite enhances RBC hypoxic ATP synthesis and the release of ATP into the vasculature: A new mechanism for nitrite-induced vasodilation. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, H1494-H1503.
99. Yanai, H.; Javitt, N.B.; Higashi, Y.; Fuda, H.; Strott, C.A. Expression of Cholesterol Sulfotransferase (SULT2B1b) in Human Platelets. Circulation 2004, 109, 92-96.
100. Tedder, T.F.; Steeber, D.A.; Chen, A.; Engel, P. The selectins: Vascular adhesion molecules. Selectins 1995, 9, 866-873.
101. Girard, J.-P.; Baekkevold, E.S.; Amalric, F. Sulfation in high endothelial venules: cloning and expression of the human PAPS synthetase. FASEB J. 1998, 12, 603-612.
102. Drayer, N.M.; Lieberman, S. Isolation of cholesterol sulfate from human aortas and adrenal tumors. J. Clin. Endocrinol. Metab. 1967, 27, 136-139.
103. Lentz, S.R. Homocysteine and vascular dysfunction. Life Sci. 1997, 61, 1205-1215.
104. McCully, K.S. Chemical pathology of homocysteine V: Thioretinamide, thioretinaco, and cystathionine synthase function in degenerative diseases. Ann. Clin. Lab. Sci. 2011, 41, 300-313.
105. Schmitz, G.; Kaminski, W.E.; Porsch-Ozcürümez, M.; Klucken, J.; Orsó, E.; Bodzioch, M.; Büchler, C.; Drobnik, W. ATP-binding cassette transporter A1 (ABCA1) in macrophages: A dual function in inflammation and lipid metabolism? Pathobiology 1999, 67, 236-240.
106. Ho, Y.K.; Brown, M.S.; Goldstein, J.L. Hydrolysis and excretion of cytoplasmic cholesteryl esters by macrophages: Stimulation by high density lipoprotein and other agents. J. Lipid Res. 1980, 21, 391-398.
107. Stanger, O.; Weger, M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin. Chem. Lab. Med. 2003, 41, 1444-1454.
108. Nonaka, H.; Tsujino, T.; Watari, Y.; Emoto, N.; Yokoyama, M. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine. Circulation 2001, 104, 1165-1170.
109. Yamamoto, M.; Hara, H.; Adachi, T. Effects of homocysteine on the binding of extracellularsuperoxide dismutase to the endothelial cell surface. FEBS Lett. 2000, 486, 159-162.
110. Wang, G.; Siow, Y.L.O.K. Homocysteine stimulates nuclear factor kB activity and monocyte chemoattractant protein-1 expression in vascular smooth muscle cells: a possible role for protein kinase. Biochem. J. 2000, 352, 817-826.
111. Ungvari, Z.; Csiszar, A.; Edwards, J.G.; Kaminski, P.M.; Wolin, M.S.; Kaley, G.; Koller, A. Increased superoxide production in coronary arteries in hyperhomocysteinemia. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 418-423.
112. Werstuck, G.H.; Lentz, S.R.; Dayal, S.; Hossain, G.S.; Sood, S.K.; Shi, Y.Y.; Zhou, J.; Maeda, N.; Krisans, S.K.; Malinow, R.; et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 2001, 107, 1263-1273.
113. Rodionov, R.N.; Lentz, S.R. The homocysteine paradox. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1031-1033.
114. Vernier, R.L.; Klein, D.J.; Sisson, S.P.; Mahan, J.D.; Oegema, T.R.; Brown, D.M. Heparan sulfate--rich anionic sites in the human glomerular basement membrane. Decreased concentration in congenital nephrotic syndrome. N. Engl. J. Med. 1983, 309, 1001-1009.
115. Antoniades, C.; Shirodaria, C.; Leeson, P.; Antonopoulos, A.; Warrick, N.; Van-Assche, T.; Cunnington, C.; Tousoulis, D.; Pillai, R.; Ratnatunga, C.; et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur. Heart J. 2009, 30, 1142-1450.
116. Yui, Y.; Aoyama, T.; Monshita, H.; Takahashi, M.; Takatsu, Y.; Kawal, C. Serum prostacyclin stabilizing factor is identical to Apolipoprotein A-I (Apo A-I) a novel function of Apo A-I.J. Clin. Invest. 1988, 82, 803-807.
117. Ali, A.B.; Zhang, Q.; Lim, Y.K.; Fang, D.; Retnam, L.; Lim, S.K. Expression of major HDLassociated antioidant PON-1 is gender dependent and regulated during inflammation. Free Radic. Biol. Med. 2003, 34, 824-829.
118. Aviram, M.; Rosenblat, M.; Billecke, S.; Erogul, J.; Sorenson, R.; Bisgaier, C.L.; Newton, R.S.;Du, B.L. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 1999, 26, 892-904.
119. Jakubowski, H. The role of paraoxonase-1 in the detoxification of homocysteine thiolactone.Adv. Exp. Med. Biol. 2010, 660, 113-127.
120. Billecke, S.; Draganov, D.; Counsell, R.; Stetson, P.; Watson, C.; Hsu, C.; la Du, B.N. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.Drug Metab. Dispos. 2007, 28, 1336-1342.
121. Gugliucci, A.; Hermo, R.; Tsuji, M.; Kimura, S. Lower serum paraoxonase-1 activity in type 2 diabetic patients correlates with nitrated apolipoprotein A-I levels. Clin. Chim. Acta 2006, 368,201-202.
122. Pollack, G. Cells, Gels and the Engines of Life; Ebner and Sons, publishers: New York, NY,USA, 2001.
123. Pries, A.R.; Secomb, T.W.; Gaehtgens, P. The endothelial surface layer. Pflugers Arch. EJP 2000, 440, 653-666.
124. Weinbaum, S.; Tarbell, J.M.; Damiano, E.R. The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 2007, 9, 121-167.
125. Vlachy, N.; Jagoda-Cwiklik, B.; Vacha, R.; Touraud, D.; Jungwirth, P.; Kunz, W. Hofmeister series and specific interactions of charged headgroups with aqueous ions. Adv. Colloid Interface Sci.2009, 146, 42-47.
126. Lee, M.; Huh, N.; Kim, J.H. Isolation of total RNA from Escherichia coli using kosmotropic Hofmeister salts. Anal. Biochem. 2008, 381, 160-162.
127. Pollack, G.H.; Figueroa, X.; Zhao, Q. Molecules, water, and radiant energy: New clues for the origin of life. Int. J. Mol. Sci. 2009, 10, 1419-1429.
128. Voeikov, V.L.; Del Giudice, E. Water respiration-the basis of the living state. Water 2009, 1, 52-75.
129. Mohri, K.; Fukushima, M. Milligauss magnetic field triggering reliable self-organization of water with long-range ordered proton transport through cyclotron resonance. IEEE T. Magn. 2003, 39, 3328-3330.
130. Vossen, C.Y.; Conard, J.; Fontcuberta, J.; Makris, M.; van Der Meer, F.J.M.; Pabinger, I.; Palareti,G.; Preston, F.E.; Scharrer, I.; Souto, J.C.; et al. Familial thrombophilia and lifetime risk ofvenous thrombosis. J. Thromb. Haemost. 2004, 2, 1526-1532.
131. Hellström, M.; Engström-Laurent, A.; Mörner, S.; Johansson, B. Hyaluronan and Collagen in Human Hypertrophic Cardiomyopathy: A Morphological Analysis. Cardiol. Res. and Pract.2012, 545219.
132. Toole B.P.; Wight, T.N.; Tammi, M.I. Hyaluronan-Cell Interactions in Cancer and Vascular Disease. J. Biol. Chem. 2002, 277, 4593-4596.
133. Sasisekharan, R.; Shriver, Z.; Venkataraman, G.; Narayanasami, U. Roles of Heparan-sulphate glycosaminoglycans in cancer. Nature Reviews 2002, 2, 521-528.
134. Lamanna, W.C.; Kalus, I.; Padva, M.; Baldwin, R.J.; Merry, C.L.R.; Dierks, T. The heparanome -The enigma of encoding and decoding heparan sulfate sulfation. J. Biotech. 2007, 129, 290-307.
135. Turnbull, J.; Powell, A.; Guimond, S. Heparan sulfate: Decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001, 11, 75-82.
136. Gorsi, B.; Stringer, S.E. Tinkering with heparan sulfate sulfation to steer development. Trends Cell Biol. 2007, 17, 173-177.
137. Couchman, J.R. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 2010, 26,89-114.
138. Teng, Y.H.; Aquino, R.S.; Park, P.W. Molecular functions of syndecan-1 in disease. Matrix Biol.2012, 31, 3-16.
139. Manon-Jensen, T.; Itoh, Y.; Couchman, J.R. Proteoglycansin health and disease. The multiple roles of syndecan shedding. FEBS J. 2010, 277, 3876-3889.
140. Iozzo, R.V.; Sanderson, R.D. Proteoglycans in cancer biology, tumor microenvironment, and angiogenesis. J. Cell Mol. Med. 2011, 15, 1013-1031.
141. Joensuu, H.; Anttonen, A.; Eriksson, M.; Mákitaro, R.; Alfthan, H.; Kinnula, V.; Leppä, S.Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 2002, 62, 5210-5217.
142. Seidel, C.; Sundan, A.; Hjorth, M.; Turesson, I.; Dahl, I.M.; Abildgaard, N.; Waage, A.; Borset, M.Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood 2000, 95,388-392.
143. Ott, V.L.; Rapraeger, A.C. Tyrosine phosphorylation of syndecan-1 and -4 cytoplasmic domains in adherent B82 fibroblasts. J. Biol. Chem. 1998, 273, 35291-35298.
144. Fitzgerald, M.L.; Wang, Z.; Park, P.W.; Murphy, G.; Bernfield, M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell Biol. 2000, 148, 811-824.
145. Iwamori, M.; Iwamori, Y.; Ito, N. Sulfated lipids as inhibitors of pancreatic trypsin and chymotrypsin in epithelium of the mammalian digestive tract. Biochem. Biophys. Res. Comm.1997, 237, 262-265.
146. Ramani, V.C.; Pruett, P.S.; Thompson, C.A.; DeLucas, L.D.; Sanderson, R.D. Heparan Sulfate Chains of Syndecan-1 Regulate Ectodomain Shedding. J. Biol. Chem. 2012, 287, 9952-9961.
147. Bode, L.; Salvestrini, C.; Park, P.-W.; Li, J.-P.; Esko, J.D.; Yamaguchi, Y.; Murch, S.;Freeze, H.H. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J. Clin. Invest. 2008, 118, 229-238.
148. Murch, S.H.; MacDonald, T.T.; Walker-Smith, J.A.; Levin. M.; Lionetti, P.; Klein, N.J. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993, 341, 711-714.
149. Wang, J.Y.; Roehrl, M.H. Glycosaminoglycans are a potential cause of rheumatoid arthritis.Proc. Natl. Acad. Sci. USA 2002, 99, 14362-14367.
150. Parildar, Z.; Uslu, R.; Tanyalcin, T.; Doganavsargil, E.; Kutay, F. The urinary excretion of glycosaminoglycans and heparan sulphate in lupus nephritis. Clin. Rheumatol. 2002, 21, 284-288.
151. Ziolkowski, A.F.; Popp, S.K.; Freeman, C.; Parish, C.R.; Simeonovic, C.J. Heparan sulfate and heparanase play key roles in mouse cell survival and autoimmune diabetes. J. Clin. Invest. 2012,122, 132-1421.
152. Gepts, W.; Lecompte, P.M. The pancreatic islets in diabetes. Am. J. Med. 1981, 70, 105-115.
153. Smeeth, L.; Juan, P.; Casas, J.P.; Hingorani, A.D. The role of infection in cardiovascular disease:more support but many questions remain. Eur. Heart J. 2007, 28, 1178-1179.
154. Kalayoglu, M.V.; Libby, P.; Byrne, G.I. Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease. JAMA 2002, 288, 2724-2731.
155. Saikku, P.; Leinonen, M.; Tenkanen, L.; Linnanmäki, E.; Ekman, M.R.; Manninen, V.; Mänttäri,M.; Frick, M.H.; Huttunen, J.K. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med. 1992, 116, 273-278.
156. Rasmussen-Lathrop, S.J.; Koshiyama, K.; Phillips, N.; Stephens, R.S. Chlamydia-dependent biosynthesis of a heparan sulphate-like compound in eukaryotic cells. Cell Microbiol. 2000, 2,137-144.
157. Jespersen, C.M.; Als-Nielsen, B.; Damgaard, M.; Hansen, J.F.; Hansen, S.; Helø, O.H.;Hildebrandt, P.; Hilden, J.; Jensen, G.B.; Kastrup, J.; et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006, 332, 22.
158. Dröge, W.; Kinscherf, R. Aberrant insulin receptor signaling and amino acid homeostasis as a major cause of oxidative stress in aging. Antioxid. Redox Sign. 2008, 10, 661-678.
159. Groffen, A.J.A.; Veerkamp, J.H.; Monnens, L.A.H.; van den Heuvel, L.P.W.J. Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol. Dial. Transplant. 1999, 14, 2119-2129.
160. Tamsma, J.T.; van den Born, J.; Bruijn, J.A.; Assmann, K.J.; Weening, J.J.; Berden, J.H.;Wieslander, J.; Schrama, E.; Hermans, J.; Veerkamp, J.H.; et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994, 37, 313-320.
161. Van den Born, J.; van Kraats, A.A.; Bakker, M.A.; Assmann, K.J.; van den Heuvel, L.P.;Veerkamp, J.H.; Berden, J.H. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate.Diabetologia 1995, 38, 161-172.
162. Singh, A.; Fridén, V.; Dasgupta, I.; Foster, R.R.; Welsh, G.I.; Tooke, J.E.; Haraldsson, B.;Mathieson, P.W.; Satchell, S.C. High glucose causes dysfunction of the human glomerular endothelial glycocalyx. Am. J. Physiol. Renal Physiol. 2011, 300, F40-F48.
163. Collins, K.D. Ions from the Hofmeister series and osmolytes: Effects on proteins in solution and in the crystallization process. Macromolecular Crystallization 2004, 34, 300-311.
164. Hart, G.W.; Akimoto, Y. The O-GlcNAc Modification. Essentials of Glycobiology, 2nd ed.; Varki, A., Cummings, R.D., Esko, J.D. Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2009; Chapter 18.
165. Buse, M.G.; Robinson, K.A.; Marshall, B.A.; Hresko, R.C.; Mueckler, M.M. Enhanced O-GlcNAc protein modification is associated with insulin resistance in GLUT1- overexpressing muscles. Am. J. Physiol. Endocrinol. Metab. 2002, 283, E241-E250.
166. Dias, W.B.; Hart, G.W. O-GlcNAc modification in diabetes and Alzheimer's disease. Mol. BioSyst. 2007, 3, 766-772.
167. Deniziak, M.A.; Barciszewski, J. Methionyl-tRNA synthetase. Acta Biochim. Pol. 2001, 48, 337-350.
168. Jakubowski, H. Proofreading in vivo: Editing of homocysteine by methionyl-tRNA synthetase in Escherichia coli. Proc. Natl. Acad. Sci. USA 1990, 87, 4504-4508.
169. Bernfield, M.; Götte, M.M.; Park, P.W.; Reizes, O.; Fitzgerald, M.L.; Lincecum, J.; Zako, M. Functions of Cell Surface Heparan Sulfate Proteoglycans. Annu. Rev. Biochem. 1999, 68, 729-777.
170. Sarafanov, A.G.; Ananyeva, N.M.; Shima, M.; Saenko, E.L, Cell Surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptorrelated protein. JBC 2001, 276, 11970-11979.
171. Herz, J.; Strickland, D.K., LRP: A multifunctional scavenger and signaling receptor. J. Clin.Invest. 2001, 108, 779-784.
172. Brickman, Y.G.; Ford, M.D.; Gallagher, J.T.; Nurcombe, V.; Bartlett, P.E.; E. Turnbull, J.E.,Structural Modification of Fibroblast Growth Factor-binding Heparan Sulfate at a Determinative Stage of Neural Development. J. Biol. Chem. 1998, 273, 4350-4359.
173. Chu, C.L.; Buczek-Thomas, J.A.; Nugent, M.A. Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. Biochem. J. 2004,379, 331-341.
174. Reitsma S.; Slaaf, D.W.; Vink, H.; van Zandvoort, M.A.; oude Egbrink, M.G. The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch. EJP 2007, 454, 345-359.
175. Cordelier, P.; Esteve, J.-P.; Rivard, N.; Marletta, M.; Vaysse, N.; Susini, C.; and Buscail, L. The activation of neuronal NO synthase is mediated by G-protein βγ subunit and the tyrosine phosphatase SHP-2. FASEB J. 1999, 13, 2037-2050.
176. Hopwood, J.J.; Dorfman, A. Glycosaminoglycan synthesis by cultured human skin fibroblasts after transformation with simian virus 40. J. Biol. Chem. 1977, 252, 4777-4785.
177. Lajoix, A.-D.; Reggio, H.; Chardès, T.; Péraldi-Roux, S.; Tribillac, F.; Roye, M.; Dietz, S.; Broca, C.;Manteghetti, M.; Ribes, G.; et al. A Neuronal isoform of nitric oxide synthase expressed in pancreatic β-cells controls insulin secretion. Diabetes 2001, 50, 1311-1323.
178. Kröncke K.D.; Kolb-Bachofen, V.; Berschick, B.; Burkart, V.; Kolb, H. Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem.Biophys. Res. Commun. 1991, 175, 752-758.
179. Gajkowska, B.; Gniadecki, R. Induction of endothelial nitric oxide synthase in perivascular mast cells in rat neurohypophysis after ischemia. Neuro. Endocrinol. Lett. 1999, 20, 189-193.
180. Wu, K.; Aoki, C.; Elste, A.; Rogalski-Wilk, A.A.; Siekevitz, P. The synthesis of ATP by glycolytic enzymes in the postsynaptic density and the effect of endogenously generated nitric oxide. Proc. Natl. Acad. Sci. USA 1997, 94, 13273-13278.
181. Damon, D.H.; D'Amore, P.A.; Wagner, J.A. Sulfated glycosaminoglycans modify growth factorinduced neurite outgrowth in PC12 cells. J. Cell Physiol. 1988, 135, 293-300.
182. Lander, A.D.; Fujii, D.K.; Gospodarowicz, D.K.; Reichardt, L.F. Characterization of a factor that promotes neurite outgrowth: Evidence linking activity to a heparan sulfate proteoglycan. J. Cell Biol. 1982, 94, 574-585.
183. Neufeld, E.F. Lysosomal storage diseases. Annu. Rev. Biochem. 1991, 60, 257-280.
184. Burbacha, B.J.; Friedl, A.; Mundhenke, C.; Rapraeger, A.C. Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biol. 2003, 22, 163-177.
185. Ignarro, L.J. Nitric oxide as a unique signaling molecule in the vascular system: A historical overview. J. Physiol. Pharmacol. 2002, 53, 503-514.
186. Wang, R. Two's company, three's a crowd: Can H2S be the third endogenous gaseous transmitter? FASEB J. 2002, 16, 1792-1798.
187. Hildebrandt, T.M.; Grieshaber, M.K. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J. 2008, 275, 3352-3361.
188. Al-Magableh, M.R.; Hart, J.L. Mechanism of vasorelaxation and role of endogenous hydrogen sulfide production in mouse aorta. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 383, 403-413.
189. Kimura, H.; Nagai, Y.; Umemura, K.; Kimura, Y. Physiological Roles of Hydrogen Sulfide:Synaptic Modulation, Neuroprotection, and Smooth Muscle Relaxation Antioxid. Redox Sign.2005, 7, 795-803.
190. Predmore, B.L.; Lefer, D.J.; Gojon, G. Hydrogen sulfide in biochemistry and medicine. Antioxid.Redox Sign. 2012, 17, 119-140.
191. Oh, G.S.; Pae, H.O.; Lee, B.S.; Kim, B.N.; Kim, J.M.; Kim, H.R.; Jeon, S.B.; Jeon, W.K.;Chae, H.J.; Chung, H.T. Hydrogen sulfide inhibits nitric oxide production and nuclear factorkappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic. Biol. Med. 2006, 41, 106-119.
192. Yamamoto, Y.; Gaynor, R.B. Role of the NF-kB pathway in the pathogenesis of human disease states. Curr. Mol. Med. 2001, 1, 287-296.
193. Bacher, S.; Schmitz, M.L. The NF-kB pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Design 2004, 10, 2827-2837.
194. Hu, L.-F.; Lu, M.; Wu, Z.-Y.; Wong, P.T.-H.; Bian, J.S. Hydrogen sulfide inhibits rotenoneinduced apoptosis via preservation of mitochondrial function. Mol. Pharmacol. 2009, 75, 27-34.
195. Martin, W.G.; Sass, N.L.; Hill, L.; Tarka, S.; Truex, R. The Synthesis of taurine from sulfate IV:An alternate pathway for taurine synthesis by the rat. Exp. Biol. Med. 1972, 141, 632-633.
196. Suzuki, T.; Nagao, A.; Suzuki, T. Human mitochondrial diseases caused by lack of taurine modification in mitochondrial tRNAs. Wiley Interdiscip. Rev. RNA 2011, 2, 376-386.
197. Hansen, S.H.; Andersen, M.L.; Cornett, C.; Gradinaru, R.; Grunnet, N. A role for taurine in mitochondrial function. J. Biomed. Sci. 2010, 17, S23.
198. Ishii, T.; Sunami, O.; Nakajima, H.; Nishio, H.; Takeuchi, T.; Hata, F. Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide. Biochem. Pharmacol. 1999, 58, 133-143.
199. Song, S.; Finkel, T. GAPDH and the search for alternative energy. Nature Cell Biol. 2007, 9,869-870.
200. Colell, A.; Ricci, J.-E.; Tait, S.; Milasta, S.; Maurer, U.; Bouchier-Hayes, L.; Fitzgerald, P.;Guio-Carrion, A.; Waterhouse, N.J.; Li, C.W.; et al. GAPDH and autophagy preserve survival after apoptotic cytochrome C release in the absence of caspase activation. Cell 2007, 129, 983-997.
201. Yin, X.M.; Ding, W.X.; Gao, W. Autophagy in the Liver. Hepatology 2008, 47, 1773-1785.
202. Ouimet, M.; Franklin, V.; Mak, E.; Liao, X.; Tabas, I.; Marcel, Y.L. Autophagy Regulates Cholesterol Efflux from Macrophage Foam Cells via Lysosomal Acid Lipase. Cell Metab. 2011,13, 655-667.
203. Takemura, G.; Miyata, S.; Kawase, Y.; Okada, H.; Maruyama, R.; Fujiwara, H. Autophagic Degeneration and Death of Cardiomyocytes in Heart Failure. Autophagy 2006, 2, 212-214.
204. Rubinsztein, D.C.; Cuervo, A.M.; Ravikumar, B.; Sarkar, S.; Korolchuk, V.; Kaushik, S.;Klionsky, D.J. In search of an "autophagomometer". Autophagy 2009, 5, 585-589.
205. Liu, H.-Y.; Han, J.; Cao, S.Y.; Hong, T.; Zhuo, D.; Shi, J.; Liu, Z.; Cao, W. Hepatic autophagy is suppressed in the presence, of insulin resistance and hyperinsulinemia: Inhibition of Fox01-dependent expression of key autophagy genes by insulin. J. Biol. Chem. 2009, 284, 31484-31492.
206. Berg, A.H.; Scherer, P.E. Adipose Tissue, Inflammation, and Cardiovascular Disease. Circ. Res.2005, 96, 939-949.
207. +)-ATPase ATP hydrolyzing activity in the human erythrocyte. Biochim. Biophys. Acta 1983, 727, 39-44.
208. Nakazato, R.; Gransar, H.; Berman, D.S.; Cheng, V.Y.; Lin, F.Y.; Achenbach, S.; Al-Mallah, M.;Budoff, M.J.; Cademartiri, F.; Callister, T.Q.; et al. Statins use and coronary artery plaque composition: Results from the International Multicenter CONFIRM Registry. Atherosclerosis 2012, 225, 148-153.
209. Levine, B.; Kroemer, G. Autophagy in the Pathogenesis of Disease. Cell 2008, 132, 27-42.
210. Kim, R.; Emi, M.; Tanabe, K.; Murakami, S. Role of the unfolded protein response in cell death.Apoptosis 2006, 11, 5-13.
211. Grimes, D.S.; Hindle, E.; Dyer, T. Sunlight, cholesterol and coronary heart disease. QJM 1996,89, 579-589.
212. Michos, E.D.; Blumenthal, R.S. Vitamin D supplementation and cardiovascular disease risk.Circulation 2007, 115, 827-828.
213. Siegel, N.; Haug, A. Aluminum interaction with calmodulin. Evidence for altered structure and function from optical and enzymatic studies. Biochim. Biophys. Acta 1983, 744, 36-45.
214. Rearick, J.I.; Jetten, A.M. Accumulation of cholesterol 3-sulfate during in vitro squamous differentiation of rabbit tracheal epithelial cells and its regulation by retinoids. J. Biol. Chem.1986, 261, 13898-13904.
215. Halliday, G.M.; Robertson, B.O.; Barnetson, R.C. Topical retinoic acid enhances, and a dark tan protects, from subedemal solar-simulated photocarcinogenesis. J. Invest. Dermatol. 2000, 114,923-927.